Edgewise Therapeutics (EWTX) vs Grifols S.A. (GRFS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Grifols S.A. (GRFS) over the past year, gaining 161.4% versus a loss of 21.8%. Over five years, EWTX leads with a +123.1% price change compared with -47.3% for GRFS. Grifols S.A. is the larger company by market cap ($5.04 billion vs $4.26 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | GRFS |
|---|---|---|
| Share price | $39.23 | $7.41 |
| Market cap | $4.26B | $5.04B |
| 1-day change | -0.86% | -1.20% |
| YTD return | +59.46% | -19.79% |
| 1-year return | +161.36% | -21.79% |
| 5-year return | +123.06% | -47.26% |
| P/E ratio (TTM) | — | 9.62 |
| Forward P/E | — | 5.14 |
| EPS (TTM) | $-1.86 | $0.77 |
| Dividend yield | 0.00% | 1.41% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-167.79M | — |
| 52-week high | $48.51 | $9.90 |
| 52-week low | $14.25 | $6.96 |
| Distance from 52-week high | -19.13% | -25.15% |
| Analyst consensus | buy | none |
| Avg. price target upside | +34.13% | +46.69% |
| Average volume | 1.35M | 580.72K |
| Shares outstanding | 108.60M | 258.22M |
| Employees | 127 | 25,258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed GRFS by 183.2 percentage points over the past year.
- Grifols S.A. offers a meaningfully higher dividend yield (1.41% vs 0.00%).
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
EWTX vs GRFS FAQ
Which is bigger, Edgewise Therapeutics or Grifols S.A.?
Grifols S.A. (GRFS) is larger, with a market capitalization of $5.04B compared with $4.26B for Edgewise Therapeutics (EWTX).
Which stock has performed better over the past year, EWTX or GRFS?
EWTX returned +161.36% over the past 12 months, compared with -21.79% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Edgewise Therapeutics or Grifols S.A.?
Grifols S.A. pays a dividend yielding 1.41%, while Edgewise Therapeutics does not currently pay a regular dividend.
Are Edgewise Therapeutics and Grifols S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.